Gilead Sciences Inc (NASDAQ:GILD)
| 78.99 Delayed Data As of Dec 08 |  +0.94 / +1.20%Today’s Change | 72.87 Today|||52-Week Range 89.74 | -7.99% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $98.5B |
Company Description
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Contact Information
Gilead Sciences, Inc. 333 Lakeside Drive Foster City California 94404 |
Employees
Shareholders
| Mutual fund holders | 55.61% |
| Other institutional | 30.65% |
| Individual stakeholders | 1.33% |
Top Executives
| Daniel P. O'Day | Chairman & Chief Executive Officer |
| Andrew D. Dickinson | Chief Financial Officer |
| Merdad V. Parsey | Chief Medical Officer |
| Flavius Martin | Executive Vice President-Research |
| Sandra K. Patterson | SVP, Chief Accounting Officer & Controller |
